N Of 2: Reflections On The Makena, Avastin Accelerated Approval Withdrawal Hearings
Executive Summary
Despite major differences in the sponsors, drugs and circumstances, the outcomes from the hearings on Makena’s continued availability and Avastin’s breast cancer indication were strikingly similar, with overwhelming votes in favor of withdrawal. In the process, however, both sponsors gained extra commercial time for their products.
You may also be interested in...
US FDA Panel Says Covis’ Makena Should Be Withdrawn – And This Time It Wasn’t Close
Fourteen of 15 advisory committee members said the preterm birth prevention drug should come off the market while a new study is conducted; panelists cited concerns about allowing continued marketing when efficacy has not been demonstrated, and they rejected Covis’ assertion that it would be harder to recruit a new study if Makena were pulled.
Makena Hearing Panel Is Deep With Maternal-Fetal Medicine Experience, As Preferred By Covis
Of 15 voting members for the Makena advisory committee, more than half have clinical expertise in MFM or perinatology. Covis had requested that a significant proportion of the panel be practicing obstetricians with MFM specialization, while CDER sought a more balanced membership.
Covis, CDER Lay Out Arguments Ahead Of Makena’s Accelerated Approval Withdrawal Hearing
The company seeks to keep Makena on the market with a narrower indication while it conducts a new randomized, controlled trial in the US, but the FDA’s drugs center says keeping the drug on the market would render a new trial infeasible and do a disservice to women at risk for preterm birth.